GALECTO, INC. GLTO 深 滬
等待開盤 11-05 09:30:00 美东时间
6.2118
-0.488
-7.29%
華盛通- 最 高6.2315
- 今 開6.16
- 成交量 3.24万股
- 最 低 5.8442
- 昨 收 6.70
- 總市值 821.45万
- 52周最高 31.70
- 市盈率 靜 --
- 換手率 2.45%
- 52周最低 2.01
- 委 比 -10.31%
- 總股本 132.24万
- 歷史最高 449.75
- 量 比 0.61
- 振 幅 5.78%
- 歷史最低 2.01
- 每 手 1
- 風險率 2.11%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多12 Health Care Stocks Moving In Wednesday's Intraday Session
Gainers Xenetic Biosciences (NASDAQ:XBIO) stock moved upwards by 137.1% to $10...
10-09 01:06
Nasdaq Gains 150 Points; US Mortgage Applications Decline
U.S. stocks traded higher this morning, with the Nasdaq Composite gaining more ...
10-08 22:22
Why Processa Pharmaceuticals Stock Rose Almost 38% Overnight?
Processa Pharmaceuticals shares jumped 37.5% after hours following a strong regular session, despite facing significant losses over the past year.
10-08 15:40
What's Going On With Nano-Cap Galecto Stock On Tuesday?
Galecto stock spiked on heavy trading with no clear news, while the company highlights funding plans, pipeline updates, and clinical priorities.
10-08 01:05
Dow Jumps Over 100 Points; McCormick Earnings Top Views
U.S. stocks traded higher this morning, with the Dow Jones index gaining more t...
10-07 22:20
Why Telomir Pharmaceuticals Shares Are Trading Higher By 31%; Here Are 20 Stocks Moving Premarket
Shares of Telomir Pharmaceuticals Inc (NASDAQ:TELO) rose sharply in pre-market ...
10-07 17:28
12 Health Care Stocks Moving In Tuesday's Intraday Session
Gainers iSpecimen (NASDAQ:ISPC) shares increased by 80.7% to $1.35 during Tues...
09-10 01:06
Galecto GAAP EPS of -$2.60
Galecto press release (NASDAQ:GLTO): Q2 GAAP EPS of -$2.60. Cash and cash equivalents as of June 30, 2025, were approximately $10.2 million. More on Galecto Seeking Alpha’s Quant Rating on Galecto Hi...
08-06 05:36
Galecto Q2 EPS $(2.60) Up From $(5.00) YoY
Galecto (NASDAQ:GLTO) reported quarterly losses of $(2.60) per share. This is a 48 percent increase over losses of $(5.00) per share from the same period last year.
08-06 04:55
Galecto Reports Second Quarter 2025 Operating and Financial Results
On August 5, 2025, Galecto, Inc. announced its Q2 2025 financial results, highlighting cash of $10.2 million and a net loss of $3.4 million. The company emphasized advancing GB3226, a dual ENL-YEATS and FLT3 inhibitor for AML, aiming for an IND filing in Q1 2026. R&D expenses decreased to $1.5 million, while general and administrative costs also fell to $2.0 million. Galecto outlined its pipeline, including GB3226 and GB1211, and stressed the nee...
08-05 20:15
